Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ: The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010, 12: 217-10.1186/ar3147.
Article
PubMed Central
PubMed
Google Scholar
Feldmann M, Maini SR: Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008, 223: 7-19. 10.1111/j.1600-065X.2008.00626.x.
Article
CAS
PubMed
Google Scholar
Buch MH: Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2010, 22: 321-329. 10.1097/BOR.0b013e328337bd01.
Article
CAS
PubMed
Google Scholar
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50: 1761-1769. 10.1002/art.20303.
Article
CAS
PubMed
Google Scholar
Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54: 2817-2829. 10.1002/art.22033.
Article
CAS
PubMed
Google Scholar
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008, 58: 2968-2980. 10.1002/art.23940.
Article
CAS
PubMed
Google Scholar
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensly J, Alecock E, Woodworth T, Alten R, OPTION Investigators: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008, 371: 987-997. 10.1016/S0140-6736(08)60453-5.
Article
CAS
PubMed
Google Scholar
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006, 54: 1390-1400. 10.1002/art.21778.
Article
CAS
PubMed
Google Scholar
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54: 2793-2806. 10.1002/art.22025.
Article
CAS
PubMed
Google Scholar
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003, 349: 1907-1915. 10.1056/NEJMoa035075.
Article
CAS
PubMed
Google Scholar
Lopez-Diego RS, Weiner HL: Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov. 2008, 7: 909-925. 10.1038/nrd2358.
Article
CAS
PubMed
Google Scholar
Yazici Y: Treatment of rheumatoid arthritis: we are getting there. Lancet. 2009, 374: 178-180. 10.1016/S0140-6736(09)60792-3.
Article
PubMed
Google Scholar
Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, Ballou LR: The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 2000, 43: 2687-2693. 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9.
Article
CAS
PubMed
Google Scholar
Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP: Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA. 2003, 100: 9044-9049. 10.1073/pnas.1332766100.
Article
PubMed Central
CAS
PubMed
Google Scholar
Honda T, Segi-Nishida E, Miyachi Y, Narumiya S: Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med. 2006, 203: 325-335. 10.1084/jem.20051310.
Article
PubMed Central
CAS
PubMed
Google Scholar
Noguchi M, Kimoto A, Kobayashi S, Yoshino T, Miyata K, Sasamata M: Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat. Eur J Pharmacol. 2005, 513: 229-235. 10.1016/j.ejphar.2005.01.058.
Article
CAS
PubMed
Google Scholar
Tsuboi H, Nampei A, Matsui Y, Hashimoto J, Kawai S, Ochi T, Yoshikawa H: Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis. Mod Rheumatol. 2007, 17: 115-122. 10.1007/s10165-007-0552-4.
Article
CAS
PubMed
Google Scholar
Taketa T, Sakai A, Tanaka S, Nakai K, Menuki K, Yamane H, Tanaka K, Nakamura T: Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular b:one mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells. J Bone Miner Metab. 2008, 26: 143-151. 10.1007/s00774-007-0808-2.
Article
CAS
PubMed
Google Scholar
Anderson GD, Keys KL, De Ciechi PA, Masferrer JL: Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009, 58: 109-117. 10.1007/s00011-009-8149-3.
Article
CAS
PubMed
Google Scholar
Page TH, Turner JJ, Brown AC, Timms EM, Inglis JJ, Brennan FM, Foxwell BM, Ray KP, Feldmann M: Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol. 2010, 185: 3694-3701. 10.4049/jimmunol.1000906.
Article
CAS
PubMed
Google Scholar
Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15: 2742-2744.
CAS
PubMed
Google Scholar
Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S, Yamamura T: Selective COX-2-inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain. 2006, 129: 1984-1992. 10.1093/brain/awl170.
Article
PubMed
Google Scholar
Alloza I, Baxter A, Chen Q, Matthiesen R, Vandenbroeck K: Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol Pharmacol. 2006, 69: 1579-1587. 10.1124/mol.105.020669.
Article
CAS
PubMed
Google Scholar
McLaughlin M, Alloza I, Quoc HP, Scott CJ, Hirabayashi Y, Vandenbroeck K: Inhibition of secretion of interleukin (IL)-12/23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP. J Biol Chem. 2010, 285: 6960-6969. 10.1074/jbc.M109.056614.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S: Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantigody-induced arthritis. Arthritis Rheum. 2007, 56: 1836-1845. 10.1002/art.22714.
Article
CAS
PubMed
Google Scholar
McLaughlin M, Vandenbroeck K: The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?. Br J Pharmacol. 2011, 162: 328-345. 10.1111/j.1476-5381.2010.01064.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wheeler MC, Rizzi M, Sasik R, Almanza G, Hardiman G, Zanetti M: KDEL-retained antigen in B lymphocytes induces a proinflammatory response: a posible role for endoplasmic reticulum stress in adaptive T cell immunity. J Immunol. 2008, 181: 256-264.
Article
CAS
PubMed
Google Scholar
Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A: The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell. 1999, 10: 1463-1475.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002, 297: 1689-1692. 10.1126/science.1073176.
Article
CAS
PubMed
Google Scholar
Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol. 2002, 169: 1459-1466.
Article
CAS
PubMed
Google Scholar
Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, Lee DM: Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med. 2006, 203: 837-842. 10.1084/jem.20052371.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kim ND, Chou RC, Seung E, Tager AM, Luster AD: A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med. 2006, 203: 829-835. 10.1084/jem.20052349.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhou JS, Xing W, Friend DS, Austen KF, Katz HR: Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis. J Exp Med. 2007, 204: 2797-802. 10.1084/jem.20071391.
Article
PubMed Central
CAS
PubMed
Google Scholar
Chou RC, Kim ND, Sadik CD, Seung E, Lan Y, Byme MH, Haribabu B, Iwakura Y, Luster AD: Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity. 2010, 33: 266-278. 10.1016/j.immuni.2010.07.018.
Article
PubMed Central
CAS
PubMed
Google Scholar
Nandakumar KS, Svensson L, Holmdahl R: Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol. 2003, 163: 1827-1837. 10.1016/S0002-9440(10)63542-0.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS: Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst. 2002, 94: 1745-1757. 10.1093/jnci/94.23.1745.
Article
CAS
PubMed
Google Scholar
Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS: The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J. 2002, 366: 831-837.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gitlin JM, Loftin CD: Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Cardiovasc Res. 2009, 81: 400-407.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wipke BT, Allen PM: Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol. 2010, 167: 1601-1608.
Article
Google Scholar
Bromley M, Fisher WD, Woolley DE: Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann Rheum Dis. 1984, 43: 76-79. 10.1136/ard.43.1.76.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M, Sillaber C, Graninger WB, Smolen JS, Valent P: Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998, 41: 233-245. 10.1002/1529-0131(199802)41:2<233::AID-ART7>3.0.CO;2-V.
Article
CAS
PubMed
Google Scholar
Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, Tanaka Y: Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. Arthritis Rheum. 2010, 62: 952-959. 10.1002/art.27331.
Article
CAS
PubMed
Google Scholar
Eklund KK: Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev. 2007, 217: 38-52. 10.1111/j.1600-065X.2007.00504.x.
Article
CAS
PubMed
Google Scholar
Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, Mclnnes IB: Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010, 184: 3336-3340. 10.4049/jimmunol.0903566.
Article
CAS
PubMed
Google Scholar
Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, Sukhova GK, Wolters PJ, Du J, Gorgun CZ, Doria A, Libby P, Blumberg RS, Kahn BB, Hotamisligil GS, Shi GP: Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009, 15: 940-945. 10.1038/nm.1994.
Article
PubMed Central
CAS
PubMed
Google Scholar
Matsukawa A, Kudo S, Maeda T, Numata K, Watanabe H, Takeda K, Akira S, Ito T: Stat3 in resident macrophages are a repressor protein of inflammatory response. J Immunol. 2005, 175: 3354-3359.
Article
CAS
PubMed
Google Scholar
Zhang Y, Ramos BF, Jakschik BA: Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 192. 258: 1957-1959.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Eng J Med. 2005, 352: 1092-1102. 10.1056/NEJMoa050493.
Article
CAS
Google Scholar
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET, Adenoma Prevention with Celecoxib Study Investigators: Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2009, 2: 310-321. 10.1158/1940-6207.CAPR-08-0206.
Article
CAS
Google Scholar
Aid S, Langenbach R, Bosetti F: Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation. 2008, 5: 17-30. 10.1186/1742-2094-5-17.
Article
PubMed Central
PubMed
Google Scholar
Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S: Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004, 114: 784-794.
Article
PubMed Central
CAS
PubMed
Google Scholar